ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Bio Path Holdings Inc

Bio Path Holdings Inc (BPTH)

1.75
0.00
(0.00%)
Closed July 23 4:00PM
1.82
0.07
( 4.00% )
Pre Market: 8:46AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
1.82
Bid
1.76
Ask
2.00
Volume
754
0.00 Day's Range 0.00
1.591 52 Week Range 25.666
Market Cap
Previous Close
1.75
Open
-
Last Trade
2
@
1.76
Last Trade Time
08:49:30
Financial Volume
-
VWAP
-
Average Volume (3m)
1,259,618
Shares Outstanding
1,656,235
Dividend Yield
-
PE Ratio
-0.18
Earnings Per Share (EPS)
-9.71
Revenue
-
Net Profit
-16.08M

About Bio Path Holdings Inc

Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The comp... Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Dover, Delaware, USA
Founded
1970
Bio Path Holdings Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BPTH. The last closing price for Bio Path was $1.75. Over the last year, Bio Path shares have traded in a share price range of $ 1.591 to $ 25.666.

Bio Path currently has 1,656,235 shares outstanding. The market capitalization of Bio Path is $2.90 million. Bio Path has a price to earnings ratio (PE ratio) of -0.18.

BPTH Latest News

Bio-Path Holdings Provides Clinical Update and Expansion Plans

Marks Meaningful Progress Across Key Clinical Trials in Multiple Cancer Indications Completes Development of Oncology Molecular Biomarkers and Prepares for Preclinical Obesity Studies HOUSTON...

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress

HOUSTON, June 14, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilizeยฎ liposomal delivery and antisense technology to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.15-7.614213197971.971.981.72585601.83214092CS
4-0.33-15.34883720932.152.151.5911136301.83623001CS
12-0.95-34.29602888092.774.551.59112596183.06197082CS
26-6.38-77.80487804888.29.98751.59113126933.77776617CS
52-23.78-92.89062525.625.6661.59114212298.9999608CS
156-128.18-98.6130172.3981.59160227931.29399105CS
260-269.78-99.3298969072271.6486.81.59157475980.64298326CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NUZENuZee Inc
$ 4.2999
(317.47%)
30.65M
DRMADermata Therapeutics Inc
$ 2.98
(129.23%)
20.88M
BBLGBone Biologics Corporation
$ 2.4277
(94.22%)
11.74M
PIRSPieris Pharmaceuticals Inc
$ 13.50
(69.17%)
1.24M
SGMOSangamo Therapeutics Inc
$ 0.59
(47.02%)
20M
NUWENewellis Inc
$ 2.60
(-37.35%)
132.81k
CONNConns Inc
$ 0.321
(-36.69%)
286.31k
VWEVintage Wine Estates Inc
$ 0.08
(-28.51%)
2.25M
ATPCAgape ATP Corporation
$ 0.16
(-25.58%)
934.84k
VSTMVerastem Inc
$ 2.68
(-25.35%)
245.63k
SLNASelina Hospitality PLC
$ 0.0255
(-1.92%)
43.09M
ALLRAllarity Therapeutics Inc
$ 0.1896
(13.87%)
39.8M
NUZENuZee Inc
$ 4.28
(315.53%)
30.67M
HOTHHoth Therapeutics Inc
$ 1.24
(27.58%)
21.8M
DRMADermata Therapeutics Inc
$ 3.00
(130.77%)
20.88M

BPTH Discussion

View Posts
Monksdream Monksdream 3 weeks ago
BPTH new 52 week low
๐Ÿ‘๏ธ0
cfoofme cfoofme 1 month ago
The low float, todayโ€™s news and myeloid leukemia news should at least stabilize the stock if nothing else. Leukemia PR should have moved it more IMO.
๐Ÿ‘๏ธ0
Here Today Here Today 1 month ago
And the news really hasnโ€™t started to make its rounds yet on wire notices. Will be interesting to see what the market feels about these pretty impressive results.
๐Ÿ‘๏ธ0
Here Today Here Today 1 month ago
Finally some good news reported today.
๐Ÿ‘๏ธ0
Here Today Here Today 2 months ago
https://stonegateinc.reportablenews.com/pr/stonegate-capital-partners-updates-coverage-on-bio-path-holdings-inc-nasdaq-bpth-q1-24
๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 2 months ago
BPTH: Indeed!! (Both the 'Low-Float' and 'Anything-Pharma' theories are now ancient history.)
๐Ÿ‘๏ธ0
Here Today Here Today 2 months ago
Crazy that this has traded so many shares and the PPS is still where it currently sits with an incredibly small float of less than 2 million sharesโ€ฆ.
๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 2 months ago
BPTH: Only 1.56-mil. Float, which might help this too. (But not quite sure if "FLOATS", per se, are trending anymore.)
๐Ÿ‘๏ธ0
Monksdream Monksdream 2 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 2 months ago
BPTH: Circa where I too grabbed it. (Just when ya think "Cancer" ain't trending anymore.)
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 2 months ago
FILLED SOME 3.34'S

MOONMAN ON THIS @ 3.50 & 3.30
๐Ÿ‘๏ธ0
saj saj 2 months ago
Boom
๐Ÿ‘๏ธ0
saj saj 3 months ago
BPTH: Bio-Path Holdings Has Been Granted Israeli Patent Number 269608 Titled "COMPOSITIONS COMPRISING P-ETHOXY NUCLEIC ACIDS FOR STAT3 INHIBITION FOR USE IN TREATING CANCER OR AUTOIMMUNE DISEASE"
BENZINGA 8:44 AM ET 5/3/2024
๐Ÿ‘๏ธ0
Awl416 Awl416 3 months ago
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
๐Ÿ‘๏ธ0
Monksdream Monksdream 3 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
๐Ÿ‘๏ธ0
tw0122 tw0122 3 months ago
New hi 3.85 700k float
๐Ÿ‘๏ธ0
Monksdream Monksdream 3 months ago
BPTH new 52 lo
๐Ÿ‘๏ธ0
Monksdream Monksdream 4 months ago
BPTH under $5
๐Ÿ‘๏ธ0
Awl416 Awl416 4 months ago
Volatility
๐Ÿ‘๏ธ0
Renee Renee 5 months ago
BPTH: effective Feb. 23,2024 a one for 20 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php
๐Ÿ‘๏ธ0
INV4 INV4 9 months ago
Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia

October 24, 2023

Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced it will host a virtual key opinion leader event to highlight the prexigebersen program and discuss advances in the treatment landscape for acute myeloid leukemia (AML). The conference call will be held on Monday, October 30, 2023 at 9:00 a.m. ET.
The event will be hosted by Peter Nielsen, Chief Executive Officer of Bio-Path, and will feature presentations and discussion with:

Jorge Cortes, M.D., Director, Georgia Cancer Center, Augusta University
Maro Ohanian, D.O., Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center

To access the live conference call, please call (833) 630-1956 (domestic) or (412) 317-1837 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Companyโ€™s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.

About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Pathโ€™s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase 1 study for solid tumors. The Companyโ€™s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND application is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3.

For more information, please visit the Company's website at http://www.biopathholdings.com.

Contact Information:

Investors

Will Oโ€™Connor
Stern Investor Relations
212-362-1200
will@sternir.com

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369

https://ih.advfn.com/stock-market/NASDAQ/bio-path-BPTH/stock-news/92348612/bio-path-holdings-to-host-virtual-key-opinion-lead

$BPTH
๐Ÿ‘๏ธ0
INV4 INV4 9 months ago
Agree! Looking good.
$BPTH
๐Ÿ‘๏ธ0
Triple nickle Triple nickle 9 months ago
Holding up pretty nice
👍️ 1
Huti Huti 9 months ago
12? Weโ€™ll see.. maybe once they get approved!
๐Ÿ‘๏ธ0
Zardiw Zardiw 9 months ago
$BPTH - #DDAmanda Video Analysis

#DDAmanda Halloween Special: https://DDAmanda.com/SignUpHalloween164.php



Z
👍️ 1
webprods webprods 9 months ago
$BPTH Finally I got answer where BPTH going. Here you are: Target price $12. 1,500.00% up from today. Reason: FDA approval for drug โ€Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc 2. Also Oct 11. 2023 News
๐Ÿ‘๏ธ0
Zardiw Zardiw 9 months ago
+++ #DDAmanda Chart on: $BPTH :

DDAmanda lets you find these early:



Z
👍️ 1
harry crumb harry crumb 9 months ago
Out, halted. Beware of a selloff folks
๐Ÿ‘๏ธ0
TimeFades TimeFades 9 months ago
Boom
๐Ÿ‘๏ธ0
dinogreeves dinogreeves 9 months ago
Good luck, I had this back in the day when it made that huge run. Been watching off and on.
๐Ÿ‘๏ธ0
jchords jchords 9 months ago
Yea. Got in pretty low on the jump. Donโ€™t have many shares. Thanks for the info
๐Ÿ‘๏ธ0
dinogreeves dinogreeves 9 months ago
They are waiting on from FDA for Fast Track Designation, they applied back in August, so it takes 60 days after the request. Either there is leak somewhere out there or just hedge run. If there is news tomorrow, I expect a huge run, closed very strong after hours.
๐Ÿ‘๏ธ0
jchords jchords 9 months ago
You know what the catalyst is?
๐Ÿ‘๏ธ0
dinogreeves dinogreeves 9 months ago
BPTH will run big tomorrow.
๐Ÿ‘๏ธ0
jchords jchords 9 months ago
Going crazy AH
๐Ÿ‘๏ธ0
jchords jchords 9 months ago
Lol
👍️ 1
Awl416 Awl416 9 months ago
OCG BPTH WTO

whoโ€™s responsible?
👍️ 1
Awl416 Awl416 9 months ago
Here we go again lol
👍️ 1
Monksdream Monksdream 10 months ago
BPTH new 52 week low
👍️ 1
REAGAN REAGAN 11 months ago
I could buy controlling interest in this company for $2.4m. Fire the CEO. Phase II is years away from a successful P-3 double blind. Of which would cost $200m. What could happen here is a consortium could come in and buy up 50% of the shares then juice the pump and sell them at $3.00 a share. But yes. Looks absolutely terrible here.
๐Ÿ‘๏ธ0
Monksdream Monksdream 11 months ago
BPTH new 52 Week low
๐Ÿ‘๏ธ0
TimeFades TimeFades 12 months ago
Bingo
๐Ÿ‘๏ธ0
TimeFades TimeFades 12 months ago
Donโ€™t get shook here this thang will have itโ€™s day soon atlesst 50% bag
๐Ÿ‘๏ธ0
TimeFades TimeFades 12 months ago
Lol
๐Ÿ‘๏ธ0
willlbone willlbone 12 months ago
Blood Bath Holdings.
๐Ÿ‘๏ธ0
AJ Freely AJ Freely 12 months ago
$BPTH - 👆Up 20% Pre-Market/ Current Price $1.29
👉Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia
๐Ÿ‘๏ธ0
cfoofme cfoofme 2 years ago
Anyway, pps has been climbing slowly & steadily the last month.
๐Ÿ‘๏ธ0
cfoofme cfoofme 2 years ago
Anyone here still holding BPTH?
๐Ÿ‘๏ธ0
mik1234 mik1234 3 years ago
86,231 shares traded today.
๐Ÿ‘๏ธ0
INFINITI INFINITI 3 years ago
BPTH $$$
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock